

AMENDMENT

The listing of the claims will replace all prior versions and listings of the claims in the application:

Listing of claims:

1 - 60 (Cancelled)

61. (Currently amended) An antibody or fragment thereof which specifically binds [an epitope comprising at least] a portion of the amino acid sequence of SEQ ID NO:121, wherein the portion comprises an epitope recognized by the antibody.

62. (Previously presented) The antibody or fragment of Claim 61 which binds to an OPG polypeptide consisting of the amino acid sequence of SEQ ID NO:121.

63. (Currently amended) An antibody or fragment thereof which specifically binds [an epitope comprising at least] a portion of the amino acid sequence of SEQ ID NO:123, wherein the portion comprises an epitope recognized by the antibody.

64. (Previously presented) The antibody or fragment of Claim 63 which binds to an OPG polypeptide consisting of the amino acid sequence of SEQ ID NO:123.

65. (Currently amended) An antibody or fragment thereof which specifically binds [an epitope comprising at least] a portion of the amino acid sequence of SEQ ID NO:125, wherein the portion comprises an epitope recognized by the antibody.

66. (Previously presented) The antibody or fragment of Claim 65 which binds to an OPG polypeptide consisting of the amino acid sequence of SEQ ID NO:125.

67. (Previously presented) The antibody or fragment of Claim 65 which binds to an OPG polypeptide consisting of residues 22-401 inclusive of SEQ ID NO:125.

68. (Previously presented) The antibody or fragment of Claim 65 which binds to an OPG polypeptide consisting of residues 22-185, 22-189, 22-194 or 22-201 inclusive as shown in SEQ ID NO:125.

69. (Previously presented) The antibody of Claims 61, 62, 63, 64, 65, 66, 67 or 68 which is a monoclonal antibody.

70. (Previously presented) The antibody of Claims 61, 62, 63, 64, 65, 66, 67 or 68 which is a chimeric antibody.

71. (Previously presented) The antibody of Claims 61, 62, 63, 64, 65, 66, 67 or 68 which is a CDR-grafted antibody.

72. (Previously presented) The antibody of Claims 61, 62, 63, 64, 65, 66, 67 or 68 which is a humanized antibody.

73. (Previously presented) The antibody of Claims 61, 62, 63, 64, 65, 66, 67 or 68 which is a human antibody.

74. (Previously presented) A method for detecting the presence of OPG in a biological sample comprising:

incubating the sample with the antibody or fragment of Claims 61, 62, 63, 64, 65, 66, 67 or 68 under conditions that allow binding of the antibody to OPG; and

detecting the bound antibody.

75. (Previously presented) A method for removing OPG from a biological sample comprising:

contacting the sample with the antibody or fragment of Claims 61, 62, 63, 64, 65, 66, 67 or 68 under conditions that allow binding of the antibody to OPG; and

removing the antibody from the sample.